ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

16 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

27 9 2023 08:09:21 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in September Investor Conference

05 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Earl Douglas as General Counsel

14 8 2023 07:30:38 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

02 8 2023 15:02:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

26 7 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

15 6 2023 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Departure of Chief Financial Officer

14 6 2023 07:00:01 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano

09 6 2023 17:25:18 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

03 6 2023 08:00:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

24 5 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

11 5 2023 10:50:32 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

03 5 2023 15:02:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

26 4 2023 09:06:38 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023

25 4 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

20 4 2023 15:05:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting

17 4 2023 09:15:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

13 4 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

30 3 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

14 3 2023 16:30:48 提供 Nasdaq GlobeNewswire